After Eli Lilly’s Explosive Earnings Report, Is It Too Late to Buy the Stock?

LLY trades at a record high above $1,300 after a third-quarter report that showed its weight loss franchise accelerating, and the stock now carries a 42x forward earnings multiple.

Mounjaro sales surged 65% and Zepbound sales jumped 49%, the two drivers behind the quarter. LLY now holds 63% of the U.S. weight loss drug market, taking share from NVO.

The bull case rests on penetration. Only 3-10% of potential patients currently access weight loss care, which implies a large pool of untapped demand if access expands. Pipeline candidates in development add further optionality, though the source gives no timelines for them.

Interpretation: a 42x forward multiple at an all-time high prices in sustained execution. The share gain against NVO and the low patient-access figure support the growth narrative, but the valuation leaves little cushion if sales growth decelerates from the 65% and 49% rates posted this quarter.